Hippocratic AI has closed a US$126m Series C at a US$3.5bn valuation, taking total funding to US$404m, as it expands its clinically safe generative AI agents across healthcare.
The round was led by Avenir Growth, with new and existing backers including CapitalG (Google’s growth fund), General Catalyst, Andreessen Horowitz, Kleiner Perkins, Premji Invest, Universal Health Services, Cincinnati Children’s Hospital Medical Center, WellSpan Health, John Doerr and Rick Klausner.
The financing was completed in two parts, following a US$235m tranche in September co-led by Braidwell and Collective Global. Additional supporters disclosed at the close include NVentures (NVIDIA’s venture arm), Analog Devices, IQT, Dauntless Ventures, Catalio Capital Management, Pennant Investors and members of Peter Diamandis’ Abundance Membership.
Founded with Flagship Pioneering, the Palo Alto-based company builds non-diagnostic, patient-facing AI agents and pairs them with rigorous safety controls.
Hippocratic AI says its platform now spans more than 1,000 clinical use cases and has handled over 115 million patient interactions without safety issues, working with 50+ provider, payor and pharma partners in six countries.
Proceeds will fund product development, global expansion and selective M&A, and further investment in the firm’s Polaris Safety Constellation architecture. Hippocratic AI also plans to broaden customer deployments.
“In our work, safety is the cornerstone,” said Hemant Taneja, chief executive of General Catalyst, which co-created Hippocratic AI. Avenir Growth co-founder Andrew Sugrue added that customer feedback suggested the company is “leading the agentic healthcare category.”
Chief executive Munjal Shah said the capital will help the company scale while adhering to its “do no harm” principles. The firm does not permit its agents to diagnose or prescribe.
